所有图片(1)
别名:
2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid, ACT-333679, MRE 269, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid
经验公式（希尔记法）:
C25H29N3O3
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
, White to light brown
溶解性
DMSO: 2 mg/mL, clear (Warmed)
储存温度
-10 to -25°C
生化/生理作用
MRE-269 (ACT-333679) is an active form of Selexipag (NS-304). MRE-269 is a potent and highly selective IP receptor agonist (selective PGI2 receptor agonist).
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Hidekazu Maruyama et al.
Life sciences, 315, 121372-121372 (2023-01-08)
Upregulated p38MAPK signaling is implicated in the accelerated proliferation of pulmonary artery smooth muscle cells (PA-SMCs) and the pathogenesis of pulmonary artery remodeling observed in pulmonary arterial hypertension (PAH). Previously, we reported that after endothelin-1 (ET-1) pretreatment, bone morphogenetic protein
Samuel N Baldwin et al.
British journal of pharmacology, 179(7), 1338-1352 (2021-11-13)
Prostacyclin mimetics express potent vasoactive effects via prostanoid receptors that are not unequivocally defined, as to date no study has considered sex as a factor. The aim of this study was to determine the contribution of IP and EP3 prostanoid
Keith Morrison et al.
The Journal of pharmacology and experimental therapeutics, 335(1), 249-255 (2010-07-28)
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension. Selexipag is highly selective for the human IP receptor in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门